Savara Inc. (NASDAQ:SVRA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Savara Inc. (NASDAQ:SVRA) have received an average rating of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $9.00.

A number of research firms have weighed in on SVRA. Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a report on Thursday, January 22nd. Wells Fargo & Company raised their price target on shares of Savara from $7.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday, December 18th. Oppenheimer set a $10.00 price objective on shares of Savara in a report on Tuesday, December 23rd. Finally, HC Wainwright reissued a “buy” rating on shares of Savara in a research report on Monday, March 16th.

Institutional Trading of Savara

A number of large investors have recently modified their holdings of the company. Osaic Holdings Inc. boosted its holdings in shares of Savara by 6.9% in the fourth quarter. Osaic Holdings Inc. now owns 32,678 shares of the company’s stock valued at $197,000 after purchasing an additional 2,098 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Savara by 3.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 69,536 shares of the company’s stock worth $420,000 after purchasing an additional 2,116 shares during the period. Graham Capital Management L.P. raised its position in Savara by 4.9% during the 4th quarter. Graham Capital Management L.P. now owns 56,013 shares of the company’s stock valued at $338,000 after purchasing an additional 2,615 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Savara by 9.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,155 shares of the company’s stock valued at $200,000 after purchasing an additional 2,859 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Savara by 48.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock worth $60,000 after buying an additional 3,205 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Trading Down 0.6%

SVRA opened at $5.25 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 11.85 and a current ratio of 11.85. The stock’s 50 day moving average price is $5.55 and its 200-day moving average price is $5.05. Savara has a one year low of $1.89 and a one year high of $7.01. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -9.91 and a beta of 0.31.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Friday, March 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). On average, equities analysts forecast that Savara will post -0.45 EPS for the current year.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.